Skip to main content

Table 1 Characteristics of incident breast cancers diagnosed during October 2006 through July 2012 at Chris Hani Baragwanath Academic Hospital Breast Clinic, Soweto, South Africa

From: Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series

Characteristic

Variable completeness (%)

Category

No. (column % among nonmissing data)

Among all incident breast cancers (N = 1247)

Sex

100

Male

12 (1.0)

Female

1232 (99.0)

Invasiveness in women

100

Non-invasive

19 (1.5)

Invasive

1216 (98.5)

Among invasive incident breast cancers in women (N = 1216)

Ethnicity

99.4

Black

1,092 (90.3)

White

49 (4.1)

Colored

46 (3.8)

Asian

22 (1.8)

Age at diagnosis (years)

 

<40

182 (15.0)

40–49

290 (23.9)

50–59

310 (25.5)

60–69

221 (18.2)

70–79

147 (12.1)

≥80

66 (5.4)

Year of diagnosis

100

2006–2007

172 (14.1)

2008–2009

431 (35.4)

2010–2012

613 (50.4)

HIV status

69.0

Negative

686 (81.8)

Positive

153 (18.2)

Stage

98.1

I

61 (5.1)

IIA

211 (17.7)

IIB

280 (23.5)

IIIA

148 (12.4)

IIIB-IIIC

385 (32.3)

IV metastases

107 (9.0)

Tumor grade

80.0

1 = Well-differentiated

106 (10.9)

2 = Moderately-differentiated

455 (46.8)

3 = Poorly-differentiated

412 (42.3)

ER

88.2

Negative

376 (35.1)

Positive: of which

696 (64.9)

Positive stain score +1

96

+2

155

+3

445

PR

87.8

Negative

500 (46.9)

Positive, of which:

567 (53.1)

Positive staining score +1

111

+2

163

+3

293

HER2

84.9

Negative, of which:

762 (74.1)

Negative stain score 0

404

+1

142

+2

216

Positive (+3)

267 (26.0)

Subtypes abbreviations:

84.5

Luminal A (ERP and/or PRP, HER2N)

551 (53.7)

Luminal B (ERP and/or PRP, HER2P)

150 (14.6)

HER2P enriched (ERN, PRN, HER2P)

117 (11.04)

Triple negative (ERN, PRN, HER2N)

209 (20.4)

  1. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2.